CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. , today announced its participation in the following upcoming investor conference:Piper Sandler's 37th Annual Healthcare ...

Three out of four adults in the United States live with conditions that can increase the risk of severe illness. 9 Chronic ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

WARNING: GRAPHIC CONTENT A grieving husband has claimed his wife died from complications of the Johnson & Johnson COVID-19 ...

Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.” ...

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

Pennsylvania’s short-term politics threaten its biotech future, driving innovation and opportunity to rival states.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64. Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron ...

Elliott Management’s Marc Steinberg is joining Honeywell’s board ahead of the industrial company’s breakup. Mergers and acquisitions were dead earlier this year before turning on a dime when President ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...